How Methodologic Differences Affect Results of Economic Analyses: A Systematic Review of Interferon Gamma Release Assays for the Diagnosis of LTBI

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Oxlade, Olivia ^a   Pinto, Marcia ^b   Trajman, Anete ^c,e   Menzies, Dick ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c GAMA FILHO UNIVERSITY   (Brazil)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION ANALYSIS MODEL; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEALTH CARE COST; HUMAN; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; METHODOLOGY; NONBIOLOGICAL MODEL; PREDICTIVE VALUE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SYSTEMATIC REVIEW; TUBERCULIN TEST;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MASS SCREENING; MODELS, STATISTICAL; QUALITY CONTROL; QUALITY-ADJUSTED LIFE YEARS; TUBERCULIN TEST;

EID: 84874747688     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056044     Document Type: Article

References (29)

1. World Health Organization (2011) Global Tuberculosis Control: WHO Report 2011.
2. World Health Organization (2010) Policy Framework for Implementing New Tuberculosis Diagnostics.
3. Drummond MF, O'Brien B, Stoddart GL, Torrance GW (2005) Methods for the Economic Evaluation of Health Care Prgrams, 2nd Edition. Oxford: Oxford Univeristy Press.
4. The Cochrane Collaboration (2011) Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Updated March 2011.
5. Pai M, Zwerling A, Menzies D, (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149: 177-184.
6. Menzies D, Pai M, Comstock G, (2007) Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146: 340-354.
7. Drummond MF, Jefferson TO, (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313: 275-283.
8. [Anonymous] (2012) European Commission- Eurostat.
9. [Anonymous] (2012) Bank of England.
10. [Anonymous] (2012) Bank of Canada.
11. [Anonymous] (2012) Bureau of Labor Statistics.
12. [Anonymous] (2012) International Monetary Fund.
13. Burgos JL, Kahn JG, Strathdee SA, Valencia-Mendoza A, Bautista-Arredondo S, et al. (2009) Targeted screening and treatment for latent tuberculosis infection using QuantiFERON-TB Gold is cost-effective in Mexico. Int J Tuberc Lung Dis 13: 962-968.
14. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH, (2009) Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 169: 179-187.
15. Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, et al. (2010) Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis 14: 471-481.
16. Diel R, Nienhaus A, Loddenkemper R, (2007) Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 131: 1424-1434.
17. Diel R, Wrighton-Smith P, Zellweger JP, (2007) Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. Eur Respir J 30: 321-332.
18. Kowada A, (2010) Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-alpha antagonist therapy. Mol Diagn Ther 14 367-373.
19. Kowada A, Deshpande GA, Takahashi O, Shimbo T, Fukui T, (2010) Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations. Mol Diagn Ther 14 229-236.
20. Kowada A, Takahashi O, Shimbo T, Ohde S, Tokuda Y, et al. (2008) Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan. Mol Diagn Ther 12: 235-251.
21. Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr, (2011) Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 184: 590-601.
22. Marra F, Marra CA, Sadatsafavi M, Moran-Mendoza O, Cook V, et al. (2008) Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis 12: 1414-1424.
23. Oxlade O, Schwartzman K, Menzies D, (2006) Interferon-gamma release assays and TB screening in high income countries: A cost effectiveness analysis. The International Journal of Tuberculosis and Lung Disease. 11: 16-26.
24. Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, et al. (2011) Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 11 435-444.
25. Pooran A, Booth H, Miller RF, Scott G, Badri M, et al. (2010) Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 10: 7.
26. Siegel JE, Weinstein MC, Russell LB, Gold MR, (1996) Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276: 1339-1341.
27. Grosse SD, (2008) Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 8: 165-178.
28. Dowdy DW, Cattamanchi A, Steingart KR, Pai M (2011) Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLOS Med 8: e1001063. PMEDICINE-D-11-00763 [pii]. doi:10.1371/journal.pmed.1001063.
29. Nienhaus A, Schablon A, Costa JT, Diel R (2011) Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res 11: 247. 1472-6963-11-247 [pii];doi:10.1186/1472-6963-11-247.